Request for Proposal: IP Strategy for FFPExtension Co.

Company Overview

Company Name	FFPExtension Co.
CEO	Ross Geller
CTO (PI)	Phoebe Buffet, PhD
Company website	PIVOT.org
Technology Summary	Reconstruction of FFPE samples using Artificial Intelligence
Major market(s)	FFPE extraction of RNA and DNA is used in the sequencing, categorization, and diagnosis of all cancers. FFPExtension Co. will first be commercialized as an RUO product with further applications in companion diagnostics.
Technology stage	Beta Testing
Primary regulatory path	Not regulated – Research Services

Context of Service Request:

FFPExtension Co. uses artificial intelligence and existing patient data to reconstruct DNA and RNA from FFPE tumor samples. Their proprietary algorithm leverages an extensive database of clinical tumors, associated sequences and mutations, which is then cross referenced with proteomic, metabolomic and phenomic patient data to resolve fragmented nucleic acid samples. TumorXTND™ will enter the market as an RUO product with further applications in clinical trials to identify otherwise inscrutable biomarkers and, finally, as a fundamental technology in clinical diagnostic platforms.

Deliverables and Reporting Requirements:

FFPExtension Co seeks a vendor to conduct a Freedom to Operate (FTO) analysis for FFPExtension Co.'s TumorXTND™ product. The vendor would conduct or have conducted on its behalf a FTO search of the publications relevant to TumorXTND™ and the patents covering TumorXTND™, which includes the technology areas of AI tools related to genomic assembly and FFPE extraction of RNA and DNA used in the classification and diagnosis of cancers. The vendor will deliver a FTO opinion after analysis of the FTO search results.

Existing Information Available for Engaged Vendor:

FFPExtension Co. is a spin off from El Diablo University. The FFPE extraction technology has been licensed from their technology transfer office. The IP is therefore shared, and not completely owned by FFPExtension Co. The algorithm, however, under consideration has been wholly developed by FFPExtension Co.

The company has attempted to conduct their own Freedom to Operate analysis but has not been successful. FFPExtension Co. will provide a list of companies that they have already identified with similar extraction technologies to interested vendors.

Vendor Qualifications:

In their proposals, vendors should describe how they are qualified to perform this work which should include prior expertise/experiences delivering FTO opinions in the areas of AI tool development and the disease areas of oncology.